The drug rosiglitazone, acting as a peroxisome proliferator-activated receptor-Y (PPAR-γ), is capable of boosting syncytialization and thereby repressing sFlt1 in placental villi from pregnancies affected by severe preeclampsia.67 These data illustrate the potential of additional drug therapies to prevent preterm delivery from preeclampsia, guided in their design by the identification of those at most risk in the early asymptomatic phase of the disease via low circulating PlGF. Here, PPARG is linked to preeclampsia.